Sangamo Therapeutics Inc (NASDAQ: SGMO)
Sangamo Therapeutics is having an overwhelmingly strong start to the trading session today, and for good reason. Data from an animal model showed strong results with regard to one of their pre-clinical treatment prospects. As a result, investors showed their excitement, leading to gains and an alert from our partners at Trade Ideas. Currently (10:05), SGMO is trading at $4.31 per share after a gain of $0.26 per share or 6.46% thus far today.
SGMO Gains On Positive Animal Model Data
As mentioned above, Sangamo Therapeutics is having an overwhelmingly strong day in the market after announcing positive data. The data came from an animal model demonstrating significant reduction of tau mRNA and tau protein expression as the result of the use of the company’s zinc finger protein transaction factor (ZFP-TF)-mediated gene regulation technology.
These results are overwhelmingly important as the results reported by SGMO are the first ever evidence of a tau lowering agent demonstrating efficacy on neuritic dystrophy in an amyloid mouse model of Alzheimer’s disease.
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on SGMO. In particular, we’re interested in following the company through its ongoing work with regard to Alzheimer’s disease as what they have shown thus far is promising. Nonetheless, we’ll continue to follow the story closely and bring you the news as it breaks!
What Do You Think?
Where do you think SGMO is headed moving forward? Join the discussion in the comments below or on StockTwits!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!
[Image Courtesy of Free Stock Photos]